La catena delle opzioni mostra i dati chiave delle opzioni azionarie di ORIC Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per ORIC Pharmaceuticals..

ORIC Pharmaceuticals (NASDAQ:ORIC) Azioni, Catena delle Opzioni

ORIC Pharmaceuticals

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals Inc

Orica Ltd

Piper Sandler analyst Brian Mullan maintains Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Neutral and lowers the price target from $40 to $38.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Dine Brands Global, Lowers Price Target to $38

<a href="https://www.bloomberg.com/news/articles/2024-11-18/biden-budget-chief-urges-congress-to-pass-disaster-relief-funds?embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2024-11-18/biden-budget-chief-urges-congress-to-pass-disaster-relief-funds?embedded-checkout=true">https://www.bloomberg.com/news/articles/2024-11-18/biden-budget-chief-urges-congress-to-pass-disaster-relief-funds?embedded-checkout=true</a>

Macro Notification

General

Reported Earlier: Biden Administration Requests $100B For Disaster Relief Programs, Including $40B For FEMA And $2B For Small Business Loans; FEMA Delayed $8.8B In Projects Due To Hurricane-Driven Cash Shortage

The Czech government recently approved a comprehensive reform of criminal law, with changes including relaxed rules on cannabis cultivation and possession. During a press conference, Justice Minister Pavel Blažek spoke about raising and favoring financial penalties over imprisonment.
"Our punishment system is outdated and diverging from the rest of the EU, which is obviously not good," Blažek said, <a href="https://www.echo24.cz/a/H5KfB/zpravy-vlada-schvalila-novela-trestniho-zakoniku-ministr-spravedlnosti-pavel-blazek-vezeni-konopi-tresty">reported</a> Echo24, according to translation.
Under the approved changes, cultivating up to three cannabis plants and possessing up to 50 grams outside the home and 25 grams inside would be legal. Cultivating four to five plants would be treated as a minor offense, but anything more than that would be considered criminal activity.
The opposition Pirate Party argued that the proposal is inadequate because allowing cultivation of several plants does not permit their harvest, as three plants could yield up to 300 grams.
"Instead of legalization and additional revenue for the budget, the government presents a botched proposal," said former Deputy Prime Minister and ex-leader of the Pirate Party Ivan Bartoš. "You can grow cannabis, but you can't harvest it. Allowing the cultivation of three cannabis plants while limiting possession to 50 grams at home is absurd. It's like being allowed to keep three hens, but if they lay more than one egg, you face a fine or jail time."
Bartoš further argued that proposal is complicating the situation for up to 600,000 medical marijuana patients. The Pirate Party plans to propose increasing the legal possession limit to 900 grams.
The government wants to implement the approved changes before the end of its term.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41295350/czech-senate-approves-restrictions-on-sale-of-kratom-and-hhc-products">Czech Senate Approves Restrictions On Sale Of Kratom And HHC Products</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Recent Calls For Regulated Cannabis Market</h2>
The news comes several months after the governing coalition confirmed it supports cannabis cultivation, but not the establishment of a regulated marijuana market. At the same time, former National Drug Coordinator Jindřich Vobořil shared he doesn't believe that the game is over for full legalization and <a href="https://www.benzinga.com/markets/cannabis/24/08/40626067/full-cannabis-legalization-not-yet-off-the-table-in-czech-republic-some-lawmakers-want-only-home" target="_blank" rel="noreferrer noopener">continues to push for it</a>.
Meanwhile, a recent study conducted by the researchers from the Faculty of Business Economics at the University of Prague concluded that the country could be <a href="https://www.benzinga.com/markets/cannabis/24/09/40879273/this-european-country-could-lose-242m-a-year-if-it-doesnt-regulate-its-marijuana-market-study-fi" target="_blank" rel="noreferrer noopener">missing out on hundreds of millions of euros </a>annually if it doesn&#8217;t establish a regulated marijuana market. As per the report a &#8220;comprehensive model,&#8221; incorporating self-cultivation, cannabis clubs and a fully commercial market, could result in "total net social benefits of CZK 5.5 billion (218 million euros; $242 million) per year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41890759/polish-parliamentary-committee-sends-cannabis-decriminalization-petition-to-prime-minister">Polish Parliamentary Committee Sends Cannabis Decriminalization Petition To Prime Minister</a></li>
</ul>
Photo: Courtesy of JESHOOTS.com via Pexels

Cannabis

Eurozone

Czech Government Legalizes Cultivation Of Three Cannabis Plants, Allows Possession Of 50 Grams

RBC Capital analyst Ben Hendrix maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Outperform and lowers the price target from $94 to $64.

ACHC

RBC Capital Maintains Outperform on Acadia Healthcare Co, Lowers Price Target to $64

Deep-pocketed investors have adopted a bullish approach towards Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LRCX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Lam Research. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 36% bearish. Among these notable options, 8 are puts, totaling $728,630, and 14 are calls, amounting to $1,401,202.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $56.0 to $105.0 for Lam Research during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Lam Research's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Lam Research's whale trades within a strike price range from $56.0 to $105.0 in the last 30 days. 
<h3>Lam Research Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731951030_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.4</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$92.00</td>
<td>$775.0K</td>
<td>360</td>
<td>1.2K</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$9.85</td>
<td>$9.8</td>
<td>$9.85</td>
<td>$80.00</td>
<td>$226.5K</td>
<td>3.0K</td>
<td>235</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$32.9</td>
<td>$30.1</td>
<td>$30.35</td>
<td>$99.00</td>
<td>$118.4K</td>
<td>68</td>
<td>39</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.0</td>
<td>$10.8</td>
<td>$10.8</td>
<td>$75.00</td>
<td>$93.9K</td>
<td>687</td>
<td>87</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.65</td>
<td>$4.55</td>
<td>$4.65</td>
<td>$67.00</td>
<td>$86.0K</td>
<td>406</td>
<td>219</td>
</tr>
</tbody>
</table>

<h3>About Lam Research</h3>
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
Following our analysis of the options activities associated with Lam Research, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Lam Research</h3>
<ul>
<li>Trading volume stands at 3,543,399, with LRCX's price up by 0.38%, positioned at $70.31.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 65 days.</li>
</ul>
<h3>What The Experts Say On Lam Research</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $94.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $100. 
&#x2A; An analyst from B. Riley Securities downgraded its action to Buy with a price target of $110. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Lam Research with a target price of $85. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Lam Research with a target price of $76. 
&#x2A; In a cautious move, an analyst from Stifel downgraded its rating to Buy, setting a price target of $100. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Lam Research, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

LRCX

Lam Research Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bearish stance on Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SBUX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Starbucks.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 50%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $1,388,257, and 4 are calls, for a total amount of $119,665.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $82.5 to $145.0 for Starbucks during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Starbucks's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Starbucks's substantial trades, within a strike price spectrum from $82.5 to $145.0 over the preceding 30 days.
<h3>Starbucks Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731951025_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$8.25</td>
<td>$7.7</td>
<td>$8.24</td>
<td>$100.00</td>
<td>$1.2M</td>
<td>0</td>
<td>1.5K</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.05</td>
<td>$5.0</td>
<td>$5.05</td>
<td>$97.50</td>
<td>$37.8K</td>
<td>5.8K</td>
<td>78</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$8.0</td>
<td>$7.9</td>
<td>$8.0</td>
<td>$100.00</td>
<td>$33.6K</td>
<td>1.2K</td>
<td>42</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$7.95</td>
<td>$7.85</td>
<td>$7.95</td>
<td>$100.00</td>
<td>$33.3K</td>
<td>1.2K</td>
<td>84</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$12.8</td>
<td>$11.9</td>
<td>$12.4</td>
<td>$100.00</td>
<td>$31.0K</td>
<td>45</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 40,000 stores across more than 80 countries as of the end of fiscal 2024. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
In light of the recent options history for Starbucks, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Starbucks</h3>
<ul>
<li>Trading volume stands at 1,850,383, with SBUX's price down by -0.01%, positioned at $98.41.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 71 days.</li>
</ul>
<h3>Expert Opinions on Starbucks</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $98.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Starbucks, which currently sits at a price target of $110. 
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Starbucks, which currently sits at a price target of $96. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Starbucks with a target price of $108. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Starbucks, targeting a price of $99. 
&#x2A; Reflecting concerns, an analyst from Redburn Atlantic lowers its rating to Sell with a new price target of $77.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Starbucks options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

SBUX

Decoding Starbucks's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VKTX, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Viking Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 22%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $58,000, and 8, calls, for a total amount of $917,315.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $72.5 for Viking Therapeutics during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Viking Therapeutics stands at 431.38, with a total volume reaching 1,992.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Viking Therapeutics, situated within the strike price corridor from $50.0 to $72.5, throughout the last 30 days.
<h3>Viking Therapeutics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731951020_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.8</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$57.50</td>
<td>$460.0K</td>
<td>83</td>
<td>1.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.7</td>
<td>$7.3</td>
<td>$7.7</td>
<td>$50.00</td>
<td>$224.0K</td>
<td>1.7K</td>
<td>299</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$13.0</td>
<td>$11.9</td>
<td>$12.1</td>
<td>$72.50</td>
<td>$89.5K</td>
<td>38</td>
<td>74</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$12.4</td>
<td>$10.8</td>
<td>$11.6</td>
<td>$59.00</td>
<td>$58.0K</td>
<td>0</td>
<td>50</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.1</td>
<td>$2.0</td>
<td>$2.1</td>
<td>$60.00</td>
<td>$32.7K</td>
<td>554</td>
<td>65</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Following our analysis of the options activities associated with Viking Therapeutics, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Viking Therapeutics</h3>
<ul>
<li>With a trading volume of 2,174,411, the price of VKTX is down by -0.56%, reaching $49.3.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 79 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Viking Therapeutics</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $96.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from HC Wainwright &amp; Co. has revised its rating downward to Buy, adjusting the price target to $90. 
&#x2A; Maintaining their stance, an analyst from HC Wainwright &amp; Co. continues to hold a Buy rating for Viking Therapeutics, targeting a price of $102. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Viking Therapeutics options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

VKTX

What the Options Market Tells Us About Viking Therapeutics

WIIM

SWVL

Swvl Holdings shares are trading higher. The company announced a $4.7 million private placement.

Piper Sandler analyst Brian Mullan maintains Performance Food Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) with a Overweight and raises the price target from $79 to $92.

PFGC

Piper Sandler Maintains Overweight on Performance Food Gr, Raises Price Target to $92

RBC Capital analyst Michael Carroll maintains American Healthcares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) with a Outperform and raises the price target from $28 to $30.

RBC Capital Maintains Outperform on American Healthcares, Raises Price Target to $30

A new <a href="https://www.nature.com/articles/s41598-024-78736-1">study</a> published in Scientific Reports revealed that while U.S. healthcare professionals are largely open to the therapeutic potential of psychedelics like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and <a href="https://www.benzinga.com/topic/mdma">MDMA</a>, their understanding of their clinical uses and risks is limited. The research, led by Erin Wang and colleagues from Johns Hopkins University, surveyed 879 healthcare providers, shedding light on current attitudes, knowledge levels, and concerns about <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted therapies (PAT)</a>.
<h3 class="wp-block-heading">Mixed Knowledge, High Expectations</h3>
The vast majority of respondents, 93%, endorsed the potential of psilocybin and 76% supported the promise of MDMA in clinical settings. However, self-reported knowledge did not align with objective assessments. While participants rated their understanding of psilocybin's therapeutic uses relatively high, only 5.5% answered all knowledge questions correctly. MDMA fared worse, with just 1.1% achieving full marks, highlighting significant knowledge gaps despite positive attitudes.
"Despite high self-rated knowledge, our findings indicate limited understanding of the potential uses, risks, and mechanisms of these substances," the authors noted. The disparity suggests a reliance on popular media and personal experiences over evidence-based resources, as nearly 70% of respondents cited media as a primary source of information.
<h3 class="wp-block-heading">Professional Role Influences Openness</h3>
Registered nurses, mental health professionals and advanced practice providers reported greater openness to integrating psychedelics into their practices than physicians. Younger professionals, particularly those aged 18-29, also expressed higher enthusiasm for clinical use compared to older age groups.
Prior psychedelics use and self-rated knowledge were strong predictors of openness, according to the multivariable regression analysis. "Personal experience and perceived understanding appear to play a key role in shaping attitudes," per the study, which noted that physicians, despite scoring higher on knowledge checks, were more conservative in their responses.
<h3 class="wp-block-heading">Concerns About Training, Costs And Risks</h3>
The primary concerns shared by respondents centered around the lack of trained providers, the financial cost of treatment and potential risks for patients with contraindications. More than 59% of healthcare professionals expressed worry about the shortage of trained personnel, echoing a broader need for <a href="https://www.benzinga.com/markets/cannabis/24/11/41820287/california-college-launches-nations-first-psychedelic-studies-degree-for-undergraduates">formalized education in psychedelic-assisted therapy</a>.
Interestingly, the potential for addiction was rated as a low concern, particularly for psilocybin, aligning with its <a href="https://www.benzinga.com/markets/cannabis/23/04/31365074/are-magic-mushrooms-addictive">lower dependence risk</a> compared to other substances. However, skepticism about MDMA's safety was more prevalent, especially following the recent decision by the Food and Drug Administration to <a href="https://www.benzinga.com/markets/cannabis/24/08/40300943/fda-rejects-mdma-for-ptsd-treatment-calls-for-more-research-on-psychedelic-therapy">delay its approval</a> for PTSD treatment pending additional trials.
<h3 class="wp-block-heading">Need for Formal Training And Evidence-Based Education</h3>
The study's findings underscored a pressing demand for comprehensive clinical training on psychedelics, as healthcare providers cited academic <a href="https://www.benzinga.com/topic/psychedelics-research">research centers and experienced clinicians</a> as their most trusted sources of information. In contrast, pharmaceutical companies ranked lowest in trust, with only 8% of respondents relying on them for data on psilocybin or MDMA.
"Systematic academic programs are needed to bridge the gap between high interest and low objective knowledge," the researchers concluded, pointing to <a href="https://www.benzinga.com/markets/cannabis/24/02/37394447/beckley-academys-open-source-psychedelic-therapy-learning-framework-is-out-whats-it-all-about-au">ongoing efforts by institutions</a> like Johns Hopkins, Yale and Columbia Universities to develop curricula for psychedelic education.
<h3 class="wp-block-heading">The Path Forward</h3>
As interest in psychedelic therapies grows, the study suggests that addressing these knowledge gaps and expanding formal training could play a pivotal role in the successful integration of PAT into mainstream healthcare. With most healthcare professionals showing support for legal medical access to both substances, a shift towards evidence-based education and training appears essential for safe and effective implementation.
Cover image made with AI

Psychedelics

Health Care

Healthcare Workers Back Psychedelics But Lack Crucial Knowledge, Study Finds

Piper Sandler analyst Brian Mullan maintains Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) with a Neutral and raises the price target from $44 to $46.

CBRL

Piper Sandler Maintains Neutral on Cracker Barrel Old, Raises Price Target to $46

Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $150 to $200.

NTRA

Piper Sandler Maintains Overweight on Natera, Raises Price Target to $200

TD Cowen analyst Joshua Jennings maintains TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) with a Buy and lowers the price target from $175 to $120.

TMDX

TD Cowen Maintains Buy on TransMedics Gr, Lowers Price Target to $120

<a href="https://fortinet-2024-analyst-day.open-exchange.net/registration" title="https://fortinet-2024-analyst-day.open-exchange.net/registration">https://fortinet-2024-analyst-day.open-exchange.net/registration</a>

Events

Trading Ideas

FTNT

Watching Fortinet; Shares Spike Lower, Company Now Presenting At Its 2024 Analyst Day, 10:15am - 1:15pm ET

Former presidential candidate Robert F. Kennedy Jr. stated at <a href="https://www.benzinga.com/24/11/42028447/peanut-the-squirrel-rallies-11-as-ufc-star-jim-miller-says-justice-for-pnut-after-winning-bout">UFC 309 in New York City</a> on Saturday that a significant part of his wealth is in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
What Happened: Kennedy, who is an outspoken proponent of Bitcoin, <a href="https://x.com/TheBTCTherapist/status/1858213810055631229">shared</a> in an interview that &#8220;most&#8221; of his wealth is in Bitcoin and that he is &#8220;committed.&#8221; 
This statement follows <a href="https://www.benzinga.com/24/07/39976220/robert-kennedy-jr-proposes-bitcoin-purchase-to-match-us-gold-reserves-an-offramp-to-the-inflationary">his participation</a> in the Bitcoin Conference 2024, where he disclosed, &#8220;After attending the Bitcoin conference, I invested all my wealth in BTC.&#8221;
In a post on X on Saturday, Kennedy <a href="https://www.benzinga.com/24/11/42028576/rfk-jr-stands-firm-on-bitcoin-as-currency-of-freedom-says-howard-lutnik-as-treasury-secretary-will-be-best-for-apex-crypto">dubbed Bitcoin the "currency of freedom,"</a> emphasizing its potential as a safeguard against U.S. national debt and inflation. He also pointed to Bitcoin's ability to challenge the dollar's dominance as the global reserve currency.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42027183/michael-saylor-predicts-bitcoin-boom-says-100k-on-the-horizon">Michael Saylor Predicts Bitcoin Boom, Says $100K On The Horizon</a>
Why It Matters: Kennedy has <a href="https://x.com/RadarHits/status/1782298931092734241?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1782298931092734241%7Ctwgr%5E910df294f4deecc29e398c9b8068bd986dcadb3a%7Ctwcon%5Es1_&amp;ref_url=https%3A%2F%2Fcointelegraph.com%2Fnews%2Frfk-jr-put-us-budget-on-blockchain">consistently praised Bitcoin</a> for its role as a hedge against economic instability. 
His proposal to <a href="https://x.com/AutismCapital/status/1816949706133799165">transfer 200,000 BTC held</a> by the Department of Justice and U.S. Marshals to the U.S. Treasury demonstrates his belief in Bitcoin as a strategic asset.
He further suggested the Treasury Department begin <a href="https://x.com/AutismCapital/status/1816951410728317217">purchasing 550 BTC daily</a> to build reserves to four million BTC.
This endorsement aligns with President-elect Donald Trump picking <a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Kennedy</a> as his Secretary of Health and Human Services. 
Trump has reportedly granted Kennedy Jr. broad authority to address systemic challenges in the U.S. healthcare system but is yet to formally nominate the former Democrat for a role in his cabinet.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42033429/exclusive-binance-ceo-richard-teng-says-2025-will-outshine-2024-for-crypto">EXCLUSIVE: Binance CEO Richard Teng Says 2025 Will Outshine 2024 For Crypto</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Robert Kennedy Jr. Says 'Most' Of His Wealth Is In Bitcoin, Is 'Committed' To The 'Currency of Freedom'

Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Overweight and lowers the price target from $115 to $69.

Reiteration

MRNA

Piper Sandler Reiterates Overweight on Moderna, Lowers Price Target to $69

<a href="https://esd.wa.gov/employer-requirements/layoffs-and-employee-notifications/worker-adjustment-and-retraining-notification-warn-layoff-and-closure-database" title="https://esd.wa.gov/employer-requirements/layoffs-and-employee-notifications/worker-adjustment-and-retraining-notification-warn-layoff-and-closure-database">https://esd.wa.gov/employer-requirements/layoffs-and-employee-notifications/worker-adjustment-and-retraining-notification-warn-layoff-and-closure-database</a>

Boeing To Layoff 2,199 Workers In Washington State Starting On December 20, 2024

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining by more than 100 points on Monday.
The Dow traded down 0.04% to 43,427.62 while the NASDAQ rose 0.69% to 18,809.65. The S&amp;P 500 also rose, gaining, 0.42% to 5,895.43.
Check This Out: <a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 1.5% on Monday.
In trading on Monday, information technology shares fell by 0.3%.
Top Headline
The NAHB/Wells Fargo Housing Market Index climbed to 46 in November, recording the highest reading in seven months, compared to 43 in October.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 237% to $1.02 after the company entered into an exclusive licensing deal with WY Biotech for immunotherapy development.</li>
<li>Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) got a boost, surging 17% to $5.55 after Baird upgraded the stock from Neutral to Outperform and raised its price target from $3 to $11.</li>
<li>Twist Bioscience Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) shares were also up, gaining 11% to $40.80 after the company reported better-than-expected fourth-quarter EPS and sales.</li>
</ul>
Equities Trading DOWN
<ul>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares dropped 54% to $0.7812. CareMax reached agreements to sell Management Services Organization and Core Centers&#8217; assets.</li>
<li>Shares of Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) were down 39% to $21.00 after the company announced it brought its high-dose gene therapy trial to a halt after a serious adverse event in a Rett syndrome patient.</li>
<li>IonQ, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NASDAQ">IONQ</a>) was down, falling 22% to $22.79.</li>
</ul>
Commodities In commodity news, oil traded up 2.8% to $68.88 while gold traded up 1.8% at $2,616.60.
Silver traded up 2.3% to $31.12 on Monday, while copper rose 0.4% to $4.0805.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.33%, Germany's DAX fell 0.32% and France's CAC 40 fell 0.11%. Spain's IBEX 35 Index fell 0.15%, while London's FTSE 100 rose 0.31%.
The Eurozone reported a trade surplus of €12.5 billion in September versus a year-ago surplus of €9.8 billion, compared to market expectations of €7.9 billion.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 falling 1.09%, Hong Kong's Hang Seng Index gaining 0.77%, China's Shanghai Composite Index declining 0.21%&nbsp; and India's BSE Sensex falling 0.31%.
Economics
The NAHB/Wells Fargo Housing Market Index climbed to 46 in November, recording the highest reading in seven months, compared to 43 in October.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42034108/this-technipfmc-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday">This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday</a></li>
</ul>

Equities

Commodities

Intraday Update

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

CMAX

HCWB

IONQ

NGNE

TWST

Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November

Piper Sandler analyst Peter Keith maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Overweight and raises the price target from $83 to $93.

Piper Sandler Maintains Overweight on Walmart, Raises Price Target to $93

Wedbush analyst David Nierengarten maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report) today and set a price target of $20.00....

Oric Pharmaceuticals (ORIC) Gets a Buy from Wedbush

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Oric Pharmaceuticals (ORIC – Research Report) and keeping the price target at ...

Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Collaborations and Strategic Clinical Advances

ORIC Pharmaceuticals (ORIC) announced the company presented a poster highlighting certain best-in-class properties of ORIC-114, a brain penetrant, ...

Oric Pharmaceuticals presents data on ORIC-114

Wells Fargo initiated coverage of Oric Pharmaceuticals (ORIC) with an Overweight rating and $20 price target The firm likes the setup for the share...

Wells starts Oric Pharmaceuticals with Overweight into 'de-risking catalysts'

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Wingstop upgraded, Estee Lauder downgraded: Wall Street's top analyst calls

"We are encouraged by the growing evidence supporting the potential best-in-class profiles of ORIC-114 and ORIC-944, and we continue to steadily ad...

Oric Pharmaceuticals reports Q3 EPS (49c), consensus (48c)

Oric Pharmaceuticals (ORIC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from...

Promising Advancements in Cancer Treatment: Buy Rating for ORIC Pharmaceuticals

ORIC Pharmaceuticals GAAP EPS of -$0.49 in-line

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a pr...

Stifel Nicolaus Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)

Oric Pharmaceuticals Inc ( ($ORIC) ) has released its Q3 earnings. Here is a breakdown of the information Oric Pharmaceuticals Inc presented to its...

Oric Pharmaceuticals Reports Strong Financial Growth and Clinical Progress

BRZE

ENLC

NVDA

ORIC

SMCI

TERN

VNDA

WING

Press Releases

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it's Board of Directors

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Comments

ORIC Pharmaceuticals

ORIC Pharmaceuticals (ORIC) Opzioni

ORIC Pharmaceuticals (NASDAQ:ORIC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO